Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Theraputic protiens/more links
from a poster
from rb post #s9104 and 9105
Therapeutic proteins: More links:
http://www.researchandmarkets.com/reportinfo.asp?cat_id=118&...
http://www.researchandmarkets.com/reportinfo.asp?cat_id=118&...
http://www.glycofi.com/sciencemarket.php
9105
Msg. 9105 of 9188
(This msg. is a reply to 9104 by ttggggtt0.)
Jump to msg. #
Excerpt from therapeutic protein link: (This is from last link I posted in Msg. # 0104)
***************************************************
1. Genomics and new antibody technologies are fueling the discovery pipeline:
Advances in genomics are beginning to contribute to an increasing number of therapeutic proteins entering clinical trials. By the mid 1990’s a few hundred therapeutic proteins were in various stages of development, a number that is expected to grow about 10 fold over the next decade.
More on redefining modern medicine (pdf)
In addition, new antibody technologies have lead to a resurgence of immunoglobulin based therapies, which generally require a significant dosage per patient and are expected to show robust growth over the coming years.
More on the new generation of therapeutic monoclonal antibodies
2. Inefficiency of current manufacturing technologies:
Current mammalian cell culture based processes are costly, frequently rely on the use of animal derived proteins at some part of the manufacturing process, and require a significant manufacturing infrastructure, which is currently operating at capacity and is expected to become growth limiting in the years to come.
More on the protein production bottleneck (pdf)
More on manufacturing capacity shortfall
Safety challenges related to the use of animal derived growth factors are an ongoing risk management issue that is costly, cumbersome and subject to a volatile supply.
********************************************************
Para. 2 deserves attention!
Hostile takeover info per phone call
as posted by a RB poster
By: exti_6_zeros
09 Nov 2003, 02:57 PM EST
Msg. 12500 of 12645
(This msg. is a reply to 12432 by hitternj.)
Jump to msg. #
hitternj, Read this hope it helps
« EXTI Message list / Reply to msg. / Post new msg. « Older / Newer »
By: pphm_make_me_rich
06 Nov 2003, 03:46 PM EST
Msg. 11493 of 12499
Jump to msg. #
Reply from company representative:
I just got off the phone with a company representative and they said that their is NO provision for a hostile takeover in the company charter. Also stated that over 40% were held by insiders (we already knew that just verified) implied that others close to the company had shares in addition to that. Said that the company would entertain any offers as was the fiduciary obligation to the shareholders but that was NOT going on now. READ NO ONE IS TRYING TO TAKE US OVER!!!! just wanted to make that clear. I thanked the person for taking time out of their hectic day to call little ol' me. And was encouraged by our recent success. Person sounded upbeat and confident. Hope this helps!!
Xenogenics boardmember/Dr. Brassfield/8/21/03/post from RB board
By: brasfild
21 Aug 2003, 06:34 PM EDT
Msg. 5678 of 17264
(This msg. is a reply to 5665 by stockstudentca.)
Jump to msg. #
Stockstudent, your posting is so misinformed that I feel obligated to respond. As a board member of EXTI subsidiary, Xenogenics, I will limit myself strictly to public information published by ourselves or our new partners.
Xenotech is actually one of the largest, privately held CRO's (contract research organizations) in the US with a reputation for excellence in drug metabolism and safety testing. They are already involved in producing and using hepatocyte testing kits involving human and other species' hepatocytes and what they need from us are our well characterized, metabolically active, immmortalized human hepatocytes. Their hepatocyte kits are based on primary cells, which are very hard to come by, and we offer them immortalized, easy to grow with media in vats, cell lines.
Our agreement with them gains us manufacturing capacity without having to build our own factory, an instant sales and marketing staff which already has contacts with the major pharmaceutical companies, administrative support and does so instantly without the huge time and money outlay required of EXTI if we were to do all this ourselves. Our royalties arrangement guarantees at least $18 million during the seven years but with no upper limit plus giving us a quick $1.5 million in very welcome cash. And since Xenotech provides manufacturing, sales, and most admin, this royalty based revenue stream flows, with very little cost, to our bottom line. This leaves Multicell free to do what it does best, research aimed at new revenue producing cell lines and, what we may be most excited about, therapeutic proteins.
Xenotech is an affiliate of Nosan Group, a Japanese company formed in the 1930's, and it is they that have the financial muscle to make this royalties guarantee. They are Japan's largest animal feed manufacturer, they are a public company 20% owned by Mitsubishi, and had gross revenue of about $1 billion last year. With revenues slowly declining during the last 5 years, Nosan boldly adopted a strategy for the 21st century of becoming a world leader in biotech and have recently formed affilliations with three US biotechs, among them Xenotech, plus biotechs in Denmark, Scotland, and Germany.
I am extremely pleased with the opportunity for rapid growth with much lessened financial risk that this agreement brings to EXTI. My advice to you, Stockstudent, is to start doing some homework!
Scott Brassfield, MD
EXTI another message board site besides Webbys'
Thanks Hannibal for all the DD and to those that made it possible also.
By: Hannibal2001
22 Oct 2003, 01:04 PM EDT
Msg. 8158 of 17263
Jump to msg. #
FWIW,
I also keep a message board for general financial info. I just started collecting data for EXTI (the main reason I got into this stock) I will be updating as a sort of repository of information. Everyone is welcome to visit or contribute info.
http://www.stacpack.com/cgi-bin/stacpack3/ikonboard.cgi?s=64e7b228c3cad3af4255ebb0a1e229d2;act=SF;f=....
I think this stock has more potential than any stock I have seen, I just would like if they could get off the BB and back on to NASDAQ as soon as they can.
Special thanks to Webby and his awesome site of info!
SZABO GREGORY buys stock 10/21/03 SEC filing
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001094722%2D03%2D000001%2Etxt&FilePath...
EXTI message board on Webbys site with GREAT DD
Thanks for all the DD to those that contributed
http://home.comcast.net/~dcmack2/exti.html
Gold Standard? in it's field
Thanks to
By: exticat
10 Oct 2003, 12:30 PM EDT
Msg. 6469 of 17261
(This msg. is a reply to 6428 by alandail.)
Jump to msg. #
Alan,
Nice overview. I would suggest expanding and refining your cell definition, however, as this is what Exten's short term success is depending upon. Immortalization, in and of itself, does not indicate that a given cell is "fully-functional." But as we know, MCT's cells have been proven to be, through testing by two major Pharmas.
There are six aspects to MCT's Fa2N-4 cells, the combination of which set them apart from all other liver cell manufacturers and suppliers; "THE GOLD STANDARD"
They are:
1) human (as opposed to porcine)
2) nontumorigenic (non-cancerous, as opposed to other's cancerous human cell lines)
3) immortilized (The ability of a genetically engineered cell line to reproduce indefinitely)
4) fully-functional (as discovered by Pfizer & now, Roche, & as opposed to others, which aren't)
5) readily available (as opposed to porcine, rat or human liver "slices")
6) cost-effective (as opposed to porcine, rat or human liver "slices")
Another important thing to consider is that MCT's proprietary cell culture media is a critical component of these cell's immortilization and viability. And don't forget, that XenoTech will be offering this proprietary culture media in their new MultiCell product launch. Just another revenue source that some of us here may have overlooked.
You are providing a great service to all the newbies here. Good Job!
Hope this helped,
EXTIcat^$^
News 7/15/03 Intellectual Property managed by Jurgensen
Exten Industries Engages BKF Jurgensen to Manage The Company’s
Intellectual Property Portfolio
Press Release
San Diego, CA – July 15, 2003 – BKF Jurgensen has been retained by Exten Industries, Inc. (OTCBB:EXTI), based in Warwick, Rhode Island, to manage its intellectual property portfolio and related business matters. BKF Jurgensen will provide patent, transactional, licensing, corporate partnering and strategic planning services for Exten and its subsidiaries, MultiCell Technologies, Inc., and Xenogenics Corporation.
“BKF Jurgensen’s biomedical background and big picture business perspective set it apart from the other firms we considered,” said Jerry Newmin, chairman and CEO of Exten. “The importance and value of any life sciences company’s IP portfolio cannot be underestimated and must be protected,” added Newmin. “With our strong therapeutic protein and liver-cell technologies, we need a firm with extensive industry expertise as well as functional specialization in patents, technology licensing and related issues. We are pleased that BKF Jurgensen has chosen to work with Exten,” he continued.
BKF Jurgensen, a division of Blanchard Krasner & French, APC, is a boutique law firm focused on the life sciences industry. With highly specialized attorneys who have themselves served in general counsel and management roles, BKF Jurgensen offers biotech, medical device and pharmaceutical companies savvy legal guidance grounded in an intimate and invaluable understanding of how the
business of science operates.
http://www.bkflaw.com/jurgensen.htm
Prior to founding BKF Jurgensen, Mr. Jurgensen was Vice President Technology Transfer and General Counsel for The Salk Institute for Biological Studies in La Jolla, California. Before that, Mr. Jurgensen was Vice President Legal, General Counsel and Corporate Secretary for Molecular Biosystems Incorporated of San Diego, California, and immediately prior to that he was Associate General Counsel at Ligand Pharmaceuticals Incorporated of San Diego, California. Prior to moving to San Diego, Mr. Jurgensen was Intellectual Property Counsel to 3M Corporation and an Associate in the law firm of Merchant
and Gould, Minneapolis, Minnesota.
Mr. Jurgensen holds a B.S. and M.S. in Biology (minor in Chemistry) and a J.D. from the University of Oregon. He is a registered Patent Attorney with extensive experience in Intellectual Property procurement, protection, enforcement and licensing as well as a strong business background with an emphasis on the biotechnology, medical device and pharmaceutical industries. Mr. Jurgensen has also written a variety of articles for the San Diego Union Tribune as well as numerous patents.
Mr. Jurgensen, and his colleagues at Blanchard, Krasner & French stand ready to assist technology-based enterprises in a wide variety of endeavors, including:
- US Patent application preparation and prosecution
- Foreign patent filings and prosecution
- Protection of Trademarks and Copyrighted Works
- Counseling on procedures to ensure protection of Trade Secrets
- Preparation and Negotiation of technology-based agreements, including confidentiality agreements, materials transfer agreements, consulting agreements, research collaboration agreements, sponsored research agreements, etc.
- Patent Strategy Counseling, including alignment of the patent portfolio to meet the client's needs, portfolio mining, cost-control procedures, etc.
- Strategy and Execution in Licensing of Intellectual Property, including preparation and negotiation of related agreements
- Strategy, Business Development and Execution of Strategic Alliances with major pharmaceutical companies and biotechnology companies
- Preparation and Negotiation of Commercial agreements, including
Clinical Trials Agreements, Co-Promotion Agreements, Development Agreements, Clinical Supply Agreements, Commercial Supply Agreements, etc."
- Due Diligence in Transactional and potential Litigation matters
- Preparation of Legal Opinions, including opinions on patentability, infringement, invalidity, etc.
- Intellectual Property Litigation
- Strategy and Counseling regarding regulatory issues (e.g., FDA, EPA,etc.)
- Executive Employment Agreements
- Corporate Formation and Maintenance
- Private Financing Transactions
- Real Estate Leases and other Transactions
- Tax Planning and Representation
Please feel free to contact Mr. Jurgensen at 858-551-2440 x325, 858-336-9097 (mobile) or tjurgensen@bkflaw.com for a no-obligation discussion of your needs, and how BKF Jurgensen can meet them
EXTI overview (11-25-03 revised)
thanks to Alandail from RB and other posters there.
The Exten Industries business is built around a revolutionary liver cell lines they have developed and patented. These offer many significant advantages, including they are:
1 - human (as opposed to porcine) liver cells that replicate and function without stimulating an immune response in the host, thereby providing a renewable source of cells to treat liver failure without immune-system side effects.
2 - nontumorigenic (non-cancerous, as opposed to other's cancerous human cell lines)
3 - immortalized (The ability of a genetically engineered cell line to reproduce indefinitely)
4 - fully-functional (as discovered by Pfizer & now, Roche, & as opposed to others, which aren't)
5 - readily available (as opposed to porcine, rat or human liver "slices")
6 - cost-effective (as opposed to porcine, rat or human liver "slices")
Here's an overview of what the liver does:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12280
These cell lines are enabling EXTI to enter (and possibly dominate) 4 major markets - I'm listing these in the order I think they will be able to enter the respective markets, starting with the market they are already in:
1 - the $3.7 billion Hepatocyte Test Kit market through their MultiCell subsidiary. Through their world wide marketing and distribution agreement with XenoTech has these test kits on the market today, with their product launched at the ISSX Meeting beginning Oct 12, 2003 and is currently being marketed worldwide. Many expect this cell line to become the gold standard for this market.
These cell lines have been validated for this specific purpose by Pfizer - http://home.comcast.net/~dcmack2/ISSXPoster.pdf - who signed a 15 year non-exclusive license for EXTI's cell lines after the validation. This validation was confirmed and extended by Hoffman-LaRoche - http://home.comcast.net/~dcmack2/Roche.html - as well as by XenoTech http://homepage.mac.com/alandail/XenoTech2003.pdf
XenoTech saw Pfizer's presentation and from that sought out EXTI to become their manufacturer. That focus enabled us to quickly identify it as a potential breakthrough, which our evaluations verified.
Thus XenoTech sought out EXTI and did their own independent testing before signing to be their marketing partner on these cell lines for hepatocyte test kits. The product is now being marketed world wide, starting with 3 important conferences.
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031010005....
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031030005....
Pfizer and XenoTech are also copresenting EXTI's technology here:
http://www.cbinet.com/events/HB405/day_one.html
and XenoTech is one of the exhibitors as well:
http://www.cbinet.com/events/HB405/Sponsors/sponsors.html
2 - the $43 billion Therapeutic Protein Production market through their MultiCell subsidiary. Being fully functional liver cells, they can generate therapeutic proteins with high yield and low cost vs. current methods and even can generate supplies where none exist today. Here are a couple of links with more on Therapeutic Proteins
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=11379
http://www.multicelltechnologies.com/30/
and here's another potential application:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12227
3 - the $2 billion bioartificial liver market through their Xenogenics subsidiary. Think of it as dialysis for the liver. Again, these fully functional immortalized liver cell lines give EXTI a major advantage in this market.
http://exten.com/exten2/sybiol.htm
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=11606
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12730
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12266
4 - the $78 billion Liver Stem Cell Transplantation market. The holy grail of liver research - to be able to regenerate damaged liver tissue.
EXTI has also been expanding their independent board. Here is news of the latest new board member
http://biz.yahoo.com/bw/031124/245268_1.html
here's what he had to say
Dr. Maggio commented, "Exten Industries' cell-based toxicological and drug screening technologies address certain critical needs among pharmaceutical and biotech companies to make more accurate assessments of the likely success of new drug candidates before they are actually placed into clinical trials. This technology promises to increase the efficiency of drug discovery and save many millions of dollars by reducing the ultimate failure rate in clinical trials, benefiting both drug companies and consumers alike."
Here's his company:
http://www.cengent.com/corporate_info.html
Some more links to look at
here's a good post from Scott Brassfield of EXTI:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=5678
Here's the unofficial EXTI investor site:
http://exti.info/
Here's the official EXTI web site:
http://exten.com/
And here's another site with a great collection of EXTI information
http://www.stacpack.com/cgi-bin/stacpack3/ikonboard.cgi?s=7760cc39b74f2fd69bb1f03558bdbdff;act=SF;f=....
News 11/24/03 New Board Member/Maggio
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 24, 2003--Exten Industries, Inc. (Exten) (OTCBB:EXTI - News) announced today that Edward T. Maggio, Ph.D, a seasoned founder, director and CEO of biotechnology companies, has joined Exten Industries board of directors.
Jerry Newmin, Chairman and CEO of Exten, enthusiastically said, "Ed Maggio has extensive experience with pioneering companies like ours, and is highly respected in bioscience, both as an entrepreneur and as a scientist. We are truly thrilled that this accomplished executive and director will bring his talents and experience to Exten's board."
Dr. Maggio is currently Chief Executive Officer and a founder of Cengent Therapeutics Inc., renamed from Structural Bioinformatics, Inc., upon the acquisition of GeneFormatics, Inc. in May 2003. Cengent Therapeutics uses advanced 3-D protein structure technologies to accelerate and significantly cut the cost of discovering new drugs. Cengent currently has pre-clinical drug discovery programs in the obesity/diabetes and anti-infective areas. He has been a founder and board member of six public and private life sciences companies in Southern California.
Dr. Maggio commented, "Exten Industries' cell-based toxicological and drug screening technologies address certain critical needs among pharmaceutical and biotech companies to make more accurate assessments of the likely success of new drug candidates before they are actually placed into clinical trials. This technology promises to increase the efficiency of drug discovery and save many millions of dollars by reducing the ultimate failure rate in clinical trials, benefiting both drug companies and consumers alike."
http://biz.yahoo.com/bw/031124/245268_1.html
Greg Szabo answers shareholders questions
By: alandail
20 Nov 2003, 01:29 PM EST
Msg. 16151 of 16171
Jump to msg. #
from a poster on the yahoo board:
Hi,
I very infrequently bother the folks at Exten with email inquiries,
but I felt I needed some answers to the following questions and here
is his response.
My Letter:
Hello,
I have been an Exten shareholder for at least 5 years now. I'm
guessing more. I would have to check my records. I have been waiting
patiently for quite some time for this type of movement and news. I
would like to ask a few questions from you with respect to some of
the PR you have released in the past month or so...perhaps even year
or so... to hopefully put some clarity as to your current and future
situation.
1.) With respect to the Pfizer deal. It's my understanding that under
the research agreement you had with them, they paid MultiCell
approximately $750,000. That agreement ended about this time last
year in which Pfizer subsequentially signed a 15 year deal. Up to
this point no details have been provided on this deal. Now I
understand that certain contract details, at the request of either
party, are not to be revealed, but could you let me know when
additional revenues from that deal are expected? If any?
2.) With respect to the XenoTech deal. Can you tell me what Exten's
commission percentage is? There has been speculation the split to be
any where from 50/50 to 25/75 (Exten/XenoTech). Also have you/they
finalized pricing? This type of information can help determine future
growth potential.
3.) What appears to be the sales cycle length on the liver cells. I
assume most pharma's would want to test it for 3-4 months before
purchasing? What appears to be the barriers to sales at this juncture?
4.) And finally, may I post your response to a couple of EXTI bulletin
boards? If not, rest assured your response to me will remain
confidential.
Regards and keep up the good work,
XXXXXXXX
Mr Szabo's response:
Mr. XXXXXXX, Thanks for your support.
1. As part of the Pfizer agreement, they, in return for the money they
paid to test and validate our cells, had the right to license the
cells for a nominal amount. This was a good deal for both companies
but especially for us since it allowed us to get the deal with
XenoTech. Additional revenues will come from Pfizer as we release and
they begin to use new products.
2. More details on the XenoTech deal will be released soon. Please
remember, XenoTech is culturing the cells, packaging and shipping, and
performing all of the sales and marketing.
3. It varies but 4 months is not a bad estimate. This is a major
change for a company and they are going to be absolutely sure before
they make any change and when they do it will be gradual.
4. yes
Greg Szabo
my comments to add to this:
The one thing to add to all of this is that at least some companies were evaluating several months before XenoTech got involved. I think the May 10-Q said 3 major pharmaceuticals were evaluating. So they're further along than companies who only began evaluating at the conference. Also, to evaluate, you have to buy some to do testing with. So an evaluation process would generate some sales, while a successful evaluation would generate more substantial sales. And we already know Roche had successful evaluation. What's unknown is if they are already adopting the cell lines or if they are doing additional evaluations.
In any case, 12 to 24 months from now, there should be widespread adoption of the cell lines. I see no reason to expect that other pharmaceuticals would find anything different than the results Pfizer, Roche and XenoTech already found. If it's worht $750k to Pfizer just to verify the cell lines, how much is it worth to have Roche start using them?
Alan
Quarterly/ Annual SEC amended reports from several days ago. Not new reports
PFE`s deal was for 15-year non-exlusive research agreement
and Xenotech's deal is $18,000,000 for 7 years
Email from Greg Szabo today:
Mr. xxx, we do not totally understand why the stock went down so rapidly. There was clearly some manipulation. We are still the same company and are trying to do the right things that will attract investors and move the stock price forward. We had a drop today for example likely because we filed amendments to some recent SEC filings. People automatically assume something is wrong and sell. The filings were simply to correct some classifications in 2001 and to clarify some wording as suggested by the SEC. Greg Szabo
This was sent to a poster on another thread RB 15704
EXTI phone # and address
Exten Industries Inc
55 Access Road, Suite 700
Warwick, RI 02886
PHONE NUMBER IS : (401) 738-7560
FAX NUMBER IS : (401) 738-7561.
Opinion of EXTI potential by poster
By: arubaviax10
18 Nov 2003, 11:39 AM EST
Msg. 15612 of 15677
Jump to msg. #
No One can deny the following facts:
1. This company has a guarantedd $18,000,000 over the next
7 years. This is the MINIMUM they will make. When the Pharmas do their DD on the Cell Lines, it is fair to say that the MAJORITY of the major PHARMA's will be using our product. So far, there have been ZERO problems with verifying the product.
2. In a comparison of debt then versus now, the company has been paying it down and this should not be a problem.
3. The company HAS BEEN ACTIVELY looking for a partner on its Sybiol Liver Device. This will bring in NEW revenue to
the company and this revenue will most likely enable the company to begin producing their Therapeutic Protein Product.
These three things simply point out that the company understands the potential. They are using their money well and are making the company much healthier. I still believe that we are looking at between $1 and $2 by the end of the year.
I expect to see upcoming PR's within the next 3 months centered around the following issues:
1. Contract from Roche
2. Contract from Asian Pharma.
3. Introduction and/or update on Therapeutic Protein Product.
4. Announcement of new partner in the Sybiol Liver device.
5. Issuance of Patent including revisions on Sybiol Liver Device.
6. Annual Report showing improving numbers but a very strong outlook.
7. Announcement of move to AMEX
Things will get much better over the next few months. All of the listed PR's above are within reach of the company.
I think we will be looking at a much happier New Year than any of us had in 2003.
SEC 8-K 11/18/03 Other Events
http://biz.yahoo.com/e/031118/exti.ob8-k.html
Form 8-K for EXTEN INDUSTRIES INC
18-Nov-2003
Other Events
ITEM 5. OTHER EVENTS
On November 17, 2003 Exten Industries, Inc. (Exten) filed an amended Form 10-KSB for its fiscal year ended November 30, 2002 and amended Form 10-QSB's for its quarters ending February 28, 2003 and May 31, 2003.
These statements were amended to correct the accounting treatment relative to the acquisition of MultiCell Associates, Inc. in the Cash Flow Statement for the fiscal year ending November 30, 2001 and to clarify certain verbiage as suggested by the SEC. There were no adjustments or changes to the Balance Sheet or Income Statement for the period ending November 30, 2001.
The specific nature of the adjustments to the Statement of Cash Flows were to reclassify $2,433,393 of cash used in operating activities related to license agreements and $1,450,000 of cash provided from financing activities for the purchase of Multicell Associates, Inc. to $750,000 of cash used in investing activities for the acquisition of license agreements, and cash used in operating activities related to changes in accounts payable and accrued liabilities ($233,343) and other assets ($50).
There were no adjustments or changes required to the financial statements in the Form 10-QSB's for the quarters ending subsequent to November 30, 2001 except to clarify certain verbiage as suggested by the SEC.
Competition? Clonetics™ Human Hepatocytes & opinions in regard to this
http://www.cambrex.com/CatNav.asp?oid=545&prodoid=Humanheps
Clonetics™ Human Hepatocytes
Human Hepatocytes are available in a variety of formats:
- Fresh suspensions
- Fresh plated on either Matrigel or Collagen
- Cryopreserved
All cells are performance tested and test negative for HIV-I, hepatitis-B & C, mycoplasma, bacteria, yeast and fungi. A certificate of analysis (CoA) and donor information is provided for each cell strain purchased
-------------------------------------------------------------
By: jcrom56
18 Nov 2003, 07:53 AM EST
Msg. 15561 of 15572
(This msg. is a reply to 15552 by Apollyon_Y2k.)
Jump to msg. #
Apollyon_Y2k
I have a friend who used to do lab work for a pharmaceutical located near Durham NC in an area known as the "Research Triangle Park". The research was associated with Duke University and was scholastic research, not industry research. The distinction has meaning if you are familiar with medical research.
I asked her what advantage there would be to a line of cells such as provided by EXTI vs. cells provided by sources such as in your post. She did not hesitate or take any time at all to formulate an answer. She said a ready supply of cells that were identical and stable would provide much more accurate test results with little need for repeated tests and aggregate results to compensate for genetic variations. If EXTI's cell lines are stable and guaranteed identical, they would be as good as you can get.
They would provide more reliable results with far fewer tests because the test cells are always identical.
Reasons I made this thread
I am a small shareholder of EXTI and find it very hard to search for any information on the Yahoo or Raging Bull threads. IHUB is the best for searching information I want to recheck or read about so here I am.
I have been in this stock for more than 6 years and plan to be in it for at least another 4 or 5 years. I feel that I want to be able to go back to search and read on this thread down the road.
If there are folks that want to discuss this stock on a regular basis,(like they do on RB) I am sure that Matt will find a nice place for this board in the future so that I can use it and continue with my copy and paste of EXTI information.
Excerpts and opinions Part 2
"""The most convincing and reassuring statement in the entire 10Q listed today is the last paragraph. This is where they bring up the future agreement with Xenotech without mentioning their name. Of course, they made the agreement. They were most likely close to closing the deal when this was originally released. They realized that by closing this deal it would make them cash flow positive. In essence, by signing the deal, they guaranteed they would make it:
The Company is also discussing agreements with distribution partners. Such an agreement will involve a cash investment by the partner to MultiCell to obtain the rights to distribute our cells. There are a number of companies that currently sell products similar to the cell products that we have. These companies have the sales and distribution forces in place and could add our product maximizing the strengths of both companies. Our goal is to find partners that can help us in all segments of the markets. These could include for example, pharmaceutical companies, contract toxicology labs, and industrial labs. The cash investments would be followed by sales and royalty revenues to maintain positive cash flow for the Company.
If there is any doubt that this company wasn't going to make it...That doubt should be replaced with confidence.
This company may not have cash flow or even strong numbers with the annual ending this month. However, this will be the last year they will report negative numbers. They made the deal that made the company. There is nowhere to go but up from here. It is a perfect time to invest in this company. They set out to get a contract to make them positive, they did it and the results have not yet hit the
10Q but they will shortly.""" (arubaviax10 RB 15486)
"""Since 1st $1,500,000 was already received, the company is guaranteed a minimum of another $16,500,000 over the next 7 years. What don't you understand?
$16,500,000/84 months=$196,428 a month to Exten over the next 7 years. I know this may not seem like alot but it is a GUARANTEED influx of cash every month.""" (ccc343 RB 15491)
"We have received orders from three major pharmaceutical companies where efficacy evaluation is currently taking place. Even with the proven results of the Pfizer research study that was concluded in November of 2002, given the major procedural change that a cell line would involve, each pharmaceutical company must satisfy itself that our cells will meet their needs."
From 10QSB "Human liver cells are the most bio-chemically complex cells in the body. One of their important functions relates to the production of proteins that are used by the body to perform vital functions such as blood clotting. MultiCell has developed culture conditions wherein cells are creating a number of these proteins."
"We are currently in discussion with numerous pharmaceutical companies about research agreements or direct purchase of our cells. Three major pharmaceutical companies are currently evaluating the cells for use in their research facilities."
By: ccc343
17 Nov 2003, 07:31 PM EST
Msg. 15516 of 15569
Jump to msg. #
aruba...It was mentioned in a post along the way that major pharma procedural changes don't happen overnight. If our cells do become the "gold standard" it will take some time for pharma's to adopt new policy and procedures on how to implement the new technology. The excerpt below proves this statement to be true...I am smiling..
Even with the proven results of the Pfizer research study that was concluded in November of 2002, given the major procedural change that a cell line would involve, each pharmaceutical company must satisfy itself that our cells will meet their needs.
By: arubaviax10
17 Nov 2003, 07:41 PM EST
Msg. 15520 of 15569
Jump to msg. #
Roche has verified however there has been no deal announced with Roche. I would expect Roche (euro pharma) and an ASIAN pharma to announce deals soon.
(Roche http://home.comcast.net/~dcmack2/Roche.html )
By: maxleverage
17 Nov 2003, 08:14 PM EST
Msg. 15525 of 15569
Jump to msg. #
"Our media, which is our own formulation and has been kept as a trade secret, is exclusively used with our immortalized cells to achieve the functions associated with the cells. The cells do not function at the same level without the media."
------------------------------------------------------------
Exten, with that statement has announced another market. In fact Roche's presentation evaluated Multicell's "MultiFunction Enhancing Medium MFE" and compared it with "HMM™ - Hepatocyte Maintenance Medium."
http://www.cambrex.com/CatNav.asp oid=530&prodoid=Hepmainmedia
--------------------------------------------------------------
By: ccc343
17 Nov 2003, 08:27 PM EST
Msg. 15528 of 15569
(This msg. is a reply to 15526 by tradenride.)
Jump to msg. #
trade...FDA approval for what?? Sybiol, yes.
Cell lines for testing liver toxicity in new drugs..NO
Only when a product will come in contact with HUMAN subjects is FDA approval needed.
-------------------------------------------------------------
By: stillpursuing
17 Nov 2003, 10:36 PM EST
Msg. 15548 of 15570
(This msg. is a reply to 15539 by tieffelhunden.)
Jump to msg. #
tieffelhunden....I am an Industrial Sales Specialist for my company. I can tell you that the average sales cycle once begun in the funnel,can take months on average to complete.
From inception until an agreement and contract are finalized the negotiation and then agreement into the close take time.
I can assure that my average sale of $65k - $100k per client closed is no where near that of the average sale for EXTI. This explains the time to close for their particular industry.
Secondly, the price structure per deal for EXTI will most certainly contain set pricing. Meaning,they will not be offering a different pricing structure for different clients. The cell plates will most likely be priced according to length of the contract and the quantities involved.If Pfizer and Roche both sign 3 year deals for the same amount of cell plates,I would assume both contracts would provide identical pricing. The only difference my be customization of the cell lines for specific testing needs.
EXTI will not want to alienate potential customers by offering special pricing to a few.
I've read the last 3 10Q's at least twice each this evening and there are MANY distinct differences in this last one from the previous two. EXTI will be closing deals IMO over the next several Q's. The product is viable and unique. One of a kind breakthrough technology that will change the way pharmas screen new drugs during testing.
Remeber the previous PR."Revolutionary breaktrough technology"."Significant worldwide interest". As soon as these "major" pharmas validate these cells for themselves, watchout above.
EXTI is going to be THE MAJOR player in the test kit niche.
JMO.
-------------------------------------------------------------
Sorry if I have duplicated some of the information as I am doing copying and pasting for all the research on this.
Do your own DD to make ANY decisions to purchase any stock.
Excerpts from 10-QSB/A 11/7/03 with some opinions
This was obviously written previous to the XenoTech deal and was reused for this filing. XenoTech is now a partner and will be culturing cell lines at their facility. (ccc343 RB 15449)
A major research effort will be to expand the quantity of proteins in an attempt to create a commercially viable product.
These cells present an immediate sales revenue opportunity. We are currently in discussion with numerous pharmaceutical companies about research agreements or direct purchase of our cells. Three major pharmaceutical companies are currently evaluating the cells for use in their research facilities.
Our plan is to partner with a major pharmaceutical company to bring our therapeutic proteins to market. The expertise of such a partner would be invaluable in completing such a program.
Additionally, a number of employees receive company stock in lieu of cash as part of their compensation to help in the effort to minimize monthly cash flow. We have successfully lowered our cash requirements while we are in this mode.
We want to add specialists for our key research areas. These strategic additions will help us expand our product offerings leading us to additional revenues and profits.
We have received orders from three major pharmaceutical companies where efficacy evaluation is currently taking place.
Human liver cells are the most bio-chemically complex cells in the body. One of their important functions relates to the production of proteins that are used by the body to perform vital functions such as blood clotting. MultiCell has developed culture conditions wherein cells are creating a number of these proteins.
Even with the proven results of the Pfizer research study that was concluded in November of 2002, given the major procedural change that a cell line would involve, each pharmaceutical company must satisfy itself that our cells will meet their needs. We believe that some of these discussions and evaluations can be brought to a conclusion in the near future. The agreements may produce cash to use for operations and research.
Most pharmaceutical companies in the world have a need for highly functional human liver cells. The engineered liver cells developed by MultiCell appear to meet many of these needs. These cells present an immediate sales revenue opportunity
The Company is also discussing agreements with distribution partners. Such an agreement will involve a cash investment by the partner to MultiCell to obtain the rights to distribute our cells. http://biz.yahoo.com/bw/030924/245267_1.html
"The Company is maintaining a conservative fiscal policy until the Company signs new pharmaceutical agreements that are being aggressively pursued. The Company has had discussions with numerous companies interested in acquiring our engineered cells for research. Sales have begun and we believe that other discussions will be brought to a conclusion in the near future. The agreements may produce cash to use for operations and research. (SALES HAVE BEGUN per this statement in the filing)
re: Sybiol
"MultiCell scientists have redesigned the chamber that will hold the hepatocytes believing that this change will allow for a healthier more functional cell. We estimate that we will need approximately $500,000 to validate the efficacy of the device. Once the device has demonstrated functionality, the Company intends to seek joint venture arrangements with major renal dialysis companies to complete the development and commercialization of this product."
From 10QSB...The cell lines are proprietary and CAN NOT be duplicated. They are ONE OF A KIND! The proprietary media is needed to make the cells funtion properly.
This answers the question of corporate piracy and any licensing agreements. They are an and will be the only company with these type cells.
"Revenues during the period came from the sale of our immortalized cell lines and our proprietary media. Our media, which is our own formulation and has been kept as a trade secret, is exclusively used with our immortalized cells to achieve the functions associated with the cells. The cells do not function at the same level without the media. Evaluation of our cell lines by potential customers is taking longer than anticipated."
The last line answers questions concerning contract releases. The evaluations are taking longer than anticipated. That means they expected to have contracts/sales already in place. The flip side is that these evaluations must be close to complete if they are already running late.
Steve......stillpursuing (RB #15474)
Business Overview states that Sybiol must go through ALL 3 phases of FDA trials.
"""aruba...of course it does. Anything that will be used on humans must go through all phases of FDA safety testing. This is nothing new.
Expect at least 2-3 years of FDA testing for efficacy of the Sybiol..
Or, if all goes extremely well, we may get FDA fast track and that time will be cut in half"""...(ccc343 RB 15480)
"""However, since cell lines to test liver toxicity will never go near humans=no FDA trials. They can and already are being sold to big pharma..""" (ccc343 RB 15482)
SEC 10-QSB/A 11/17/03 Management Discussion and Analysis
http://www.sec.gov/Archives/edgar/data/811779/000108638003000073/extq0503r.htm
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS
This Quarterly Report on Form 10-QSB contains forward-looking statements that involve risks and uncertainties. These statements are based on certain assumptions that may prove to be erroneous and are subject to certain risks including, but not limited to, the Company's ability to complete and fund its research and development. The Company's actual results may differ significantly from the results discussed in the forward-looking statements.
Overview
Business:
We were incorporated in Delaware on April 28, 1970 under the name of Exten Ventures, Inc. Until recently, our primary focus has been the development of a synthetic bio-liver device, known as the Sybiol®, through our majority-owned subsidiary, Xenogenics Corporation. Because this technology must be tested for safety and efficacy in three phases of human clinical trials that are reviewed by the Food and Drug Administration, we believe it will take approximately three to five years to develop, test and commercialize this device. One of the primary reasons a device such as ours takes so long to get to market is the availability of qualified patients. With our recent acquisition of MultiCell Technologies and its development of liver-related cell lines, we are now focusing on the opportunities afforded us with the engineered liver cell lines that are currently available for drug discovery and toxicology testing. Since there are nonhuman uses for these cells, and there are no regulatory issues preventing immediate sales, licensing and direct sales have begun. These cells are our only commercial product. They are currently cultured at the MultiCell facility but as volume grows, we will look for a partner to culture the cells in greater quantities.
- 9 -
_______________________________________________________________________________
MultiCell will continue to improve and expand the number of cell lines to meet the testing and research needs of the pharmaceutical industry. Human liver cells are the most bio-chemically complex cells in the body. One of their important functions relates to the production of proteins that are used by the body to perform vital functions such as blood clotting. MultiCell has developed culture conditions wherein cells are creating a number of these proteins. A major research effort will be to expand the quantity of proteins in an attempt to create a commercially viable product.
Scientists believe there will be a great opportunity to use stem cells as a source of highly functional hepatocytes. One use for these cells would be for transplant as a treatment for certain diseases. These cells would also have value to the pharmaceutical industry in toxicology testing. MultiCell is focusing on adult liver stem cells. There are no controversy or supply issues with these cells as there is with fetal or embryonic stem cells. This is a long-term project.
Xenogenics Corporation, our majority-owned subsidiary, is a developmental stage enterprise that owns all of the rights to the Sybiol synthetic bio-liver device for which a patent is pending in 15 countries, including the United States. Xenogenics is currently owned as follows:
Exten Industries, Inc.
56.4%
Kestrel Equity Partners, Ltd.
21.7%
Jack Schaps
12.5%
W. Gerald Newmin
8.0%
Others
1.4%
The underlying concept of the liver device is that an artificial liver can act as a substitute liver for a patient whose own liver is healing from injury or disease. In addition, the device is intended for use as a "bridge" for transplant patients awaiting a donor organ. This is accomplished by exposing the plasma portion of the blood to functioning liver cells. The cells perform the functions of the damaged liver of the patient. Theoretically, the artificial device can replace the essential functions of the normal liver. The key to our device or other devices attempting to gain approval, is the functionality of the cells The device may also be used to assist and improve the quality of life for patients with chronic liver disease or episodic liver trauma. Xenogenics has a Research and Development Agreement and a Supplier Agreement with MultiCell under which MultiCell will supply engineered human liver cell lines and optimize the interface between these cell lines and the Sybiol device. An engineered human cell line is expected to eliminate variability in patient treatment and limit the viral risks associated with primary porcine hepatocytes.
Some of our products will be subject to regulation in the United States by the FDA and by comparable regulatory authorities in foreign jurisdictions. Future products including Therapeutic Plasma Proteins, stem cell transplantation and the Sybiol device will be regulated under the Public Health Service Act and the Food, Drug and Cosmetic Act. The use of engineered liver cells generated by MultiCell for this application will also be regulated by the FDA. Development of a therapeutic product for human use is a multi-step process. After acceptance of a plan by the FDA, animal and human testing must be completed. Human clinical investigations typically involve three phases. Phase I is conducted to evaluate the safety of the experimental product in humans. If acceptable product safety is demonstrated, the Phase II and III studies are initiated. These trials are designed to evaluate the effectiveness of the product in the treatment of a given disease and, typically, are well controlled, closely monitored studies. As Phase II trials are successfully completed, Phase III studies will commence with expanded controlled and uncontrolled trials which are intended to gather additional information about safety and efficacy in order to evaluate the overall risk/benefit relationship of the experimental product and provide an adequate basis for physician labeling. These studies also may compare the safety and efficacy of the experimental device with currently available products. While it is not possible to estimate the amount of time that will be required to complete Phase I, II and III studies, this process, which is often dependant on the availability of patients, often lasts three to five years.
- 10 -
_______________________________________________________________________________
We have not yet begun human clinical trials for the Sybiol device. We intend to begin such trials by the end of 2004 upon completion of the redesign and validation of the device. MultiCell scientists have redesigned the chamber that will hold the hepatocytes believing that this change will allow for a healthier more functional cell. We estimate that we will need approximately $500,000 to validate the efficacy of the device. Once the device has demonstrated functionality, the Company intends to seek joint venture arrangements with major renal dialysis companies to complete the development and commercialization of this product.
Presently, our focus is on the generation of short-term revenue to stabilize our cash position. Most pharmaceutical companies in the world have a need for highly functional human liver cells. The engineered liver cells developed by MultiCell appear to meet many of these needs. These cells present an immediate sales revenue opportunity. We are currently in discussion with numerous pharmaceutical companies about research agreements or direct purchase of our cells. Three major pharmaceutical companies are currently evaluating the cells for use in their research facilities.
With respect to MultiCell's efforts on behalf of Xenogenics, before human studies may begin, the cells provided for the Sybiol system by MultiCell will be subjected to the same scrutiny as the Sybiol device. MultiCell will need to demonstrate sufficient process controls to meet strict standards for a complex medical system. This means the cell production facility will need to meet the same standards as those pertaining to a pharmaceutical company . Our plan is to partner with a major pharmaceutical company to bring our therapeutic proteins to market. The expertise of such a partner would be invaluable in completing such a program.
We have operated and will continue to operate by minimizing expenses as we move towards a cash positive position. The largest expenses relate to personnel and to meeting the legal and reporting requirements of being a public company. By utilizing consultants whenever possible, and asking employees to manage multiple responsibilities, operating costs are kept low. Additionally, a number of employees receive company stock in lieu of cash as part of their compensation to help in the effort to minimize monthly cash flow. We have successfully lowered our cash requirements while we are in this mode.
Once we have achieved a positive cash position, we intend to gradually add scientific and support personnel. We want to add specialists for our key research areas. These strategic additions will help us expand our product offerings leading us to additional revenues and profits. Of course as revenues increase, administrative personnel will be necessary to meet the added workload. Other expenses, such as sales and customer service, will increase commensurate with increased revenues.
SEC 10KSB/A 11/17/03 Annual Report
http://biz.yahoo.com/e/031117/exti.ob10ksb_a.html
Form 10KSB/A for EXTEN INDUSTRIES INC
--------------------------------------------------------------------------------
17-Nov-2003
Annual Report
Results of Operations.
The following discussion is included to describe our consolidated financial position and results of operations. The consolidated financial statements and notes thereto contain detailed information that should be referred to in conjunction with this discussion.
Year Ended November 30, 2002, Compared to Year Ended November 30, 2001
Revenues. Total revenues increased to $804,538 for the fiscal year ended November 30, 2002 compared to $113,327 for the fiscal year ended November 30, 2001. These revenues came primarily from a collaborative research agreement between our MultiCell subsidiary and Pfizer Inc. which was entered into and completed during the fiscal year ended November 30, 2002. The research contract with Pfizer was to evaluate the efficacy of our liver cells for drug testing. We are negotiating a license agreement with Pfizer allowing them to continue to use the cell lines for research. In addition, MultiCell began to receive revenues from licensing fees and product sales that management expects will be part of a continuous revenue stream. Accordingly, due to the level of and the recurring nature of the revenue, the Company is no longer considered a development stage company for accounting purposes.
Operating Expenses. Total operating expenses increased to $2,241,310 for the fiscal year ended November 30, 2002 from $1,756,057 for the fiscal year ended November 30, 2001. The increase is primarily due to the inclusion of expenses from MultiCell that are not included in the prior year numbers that are being compared. The Company did not add personel to work on the research project for Pfizer. Responsibilities were simply shifted from one project to another. Such expenses include general and administrative expenses, research and development costs and depreciation and amortization.
The increase of $99,498 in general and administrative expenses for the fiscal year ended November 30, 2002 over the prior year is primarily attributable to salaries, benefits and operational expenses at MultiCell and Exten. The increase of $251,416 in research and development over the prior year expenses is attributable primarily to continued work on our engineered liver cell lines. In addition, the $134,339 increase in depreciation and amortization over the prior year is due to the additional amortization expense related to the amortization of the license agreement recorded in connection with the acquisition of MultiCell.
Other income/expense. Interest expense for the fiscal year ended November 30, 2002, was $124,464, which represents an increase of $30,876 over the prior fiscal year. This increase is attributable to interest expense incurred on the funds borrowed for the acquisition and operation of MultiCell, as well as other new notes payable which were not outstanding during the prior year. Interest income for the fiscal year ended November 30, 2002, was $74,731, as compared to $79,262 for the prior year. This decrease is attributable to interest earned on notes receivable from loans made in prior years and during the current fiscal year. The amortization of the discount on notes payable for the fiscal year ended November 30, 2002, was $132,142, as compared to $25,163 for the prior year. The increase is due to increase of financing obtained during year 2002 and the impact of a full year's amortization of the debt discount related to 2001 financings. Minority interest in loss of subsidiary for the fiscal year ended November 30, 2002 was $12,334, as compared to $169,686 for the prior year. This decrease is due to the subsidiary's decrease in activity and resultant loss this year.
Net loss. Net loss for the fiscal year ended November 30, 2002, was $1,576,663, as compared to a net loss of $1,609,383 for the prior year, representing a decrease in net loss of $32,720. This decrease is attributable to the higher revenues attained during the year, as discussed in greater detail above, which was partially offset by greater expenses associated with the combined organizations.
Liquidity and Capital Resources
In the past, our cash needs have been managed primarily through the issuance of debt or equity securities. Although the parties (some of whom are related parties) have shown a commitment to our Company, and may therefore be willing to provide additional financing should be need it, we do not have formal commitments from any of these parties nor can we provide any assurance that these sources may continue to loan or invest monies, there is no certainty that such funds will be available in the future. The Company is maintaining a conservative fiscal policy until the Company signs new pharmaceutical agreements that are being aggressively pursued. The Company has had discussions with numerous companies interested in acquiring our engineered cells for research. Sales have begun and we believe that other discussions will be brought to a conclusion in the near future. The agreements may produce cash to use for operations and research.
The Company is also discussing agreements with various potential distribution partners. Such an agreement will involve a cash investment by the partner to MultiCell to obtain the rights to our cells. There are a number of companies that currently market products similar to the cell products that we have to our potential customers. These companies have the sales and distribution forces in place and could add our product maximizing the strengths of both companies. Our goal is to find partners that can help us in all segments of the markets. These could include, for example, pharmaceutical companies, contract toxicology labs, and industrial labs. The cash investments would be followed by sales and royalty revenues to maintain positive cash flow for the Company.
- The Company anticipates that the revenue generated by MultiCell, along with the potential cash investments by potential distribution partners will be sufficient for the Company to operate through fiscal 2003. To the extent that additional funds may be required, the Company hopes to be able to secure the needed funds through the sale of additional equity securities or debt, as noted above. In addition, where possible, the Company may continue to satisfy obligations through the issuance of additional common stock.
Research Agreements
In October 2002, MultiCell Technologies was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to study the production of therapeutic plasma proteins by immortalized, non-tumorigenic human hepatocytes. The aim of the SBIR award is to compare the function of MultiCell's hepatocyte-derived products to recombinant and plasma-derived therapeutic plasma proteins. The grant is for $133,000 and will be paid over the grant period of one year as the work is performed. At November 30, 2002, work had not yet commenced.
Notes Payable
As of November 30, 2002, the Company, or its subsidiary, Xenogenics, are in default on notes payable with a principal balance of $129,000. Through March 31, 2003, such lenders have not demanded payment and the Company continues to accrue interest on all notes payable.
During Fiscal Year 2002, the Company entered into 33 convertible promissory notes for a total of $547,500 with interest accruing at 10% per annum. The principal and interest are payable in 2005, three years after the inception of the notes. The lenders may convert the principal and any unpaid interest due into the Company's common stock. The conversion price varies from $.10 to $.20 per share. Additionally, the Company issued 5,170,000 common stock warrants convertible at $.10 per share. The Company initially increased additional paid-in capital by $127,236 based on the fair value of the warrants and reduced the carrying value of the convertible promissory notes payable by the same amount for the debt discount attributable to the fair value of the warrants. In addition, after the initial allocation of the loan proceeds to the relative fair value of the warrants and the notes in 2002, the fair value of the Company's common stock exceeded the effective conversion price of certain notes on their respective dates of issuance. Such excess, which represents beneficial conversion rights, totaled $39,837, which the Company recorded by increasing both the debt discount and additional paid-in capital by that amount. The debt discount attributable to the warrants and the beneficial conversion rights is being amortized to interest expense over the term of the convertible notes.
On April 1, 2002, the Company negotiated a Promissory Note with its legal counsel, Jeffers, Shaff & Falk, LLP, now named Falk, Shaff & Ziebell, LLP, for legal services rendered through March 31, 2002. The note is for $33,392 at 10% per annum and was due and payable June 30, 2002. The Company did not pay the note and renegotiated the terms the terms on February 1, 2003. The new note voids the previous note and its terms and starts a new note of $50,000 involving monthly payments beginning March 2003 until the note is paid in full.
Old News article 4/14/23
PharmaLive
Exten Industries Inc. Reports Pharmaceutical Validation, Commercialization, Record Revenues and Moves beyond Development Stage Classification
WARWICK, R.I., April 14, 2003 -- Exten Industries Inc. (Exten) (OTCBB:EXTI) released consolidated financial results for its fiscal year ended Nov. 30, 2002.
Most significant is growth in revenues to over $800,000 for the year, causing the company's independent accountants, J.H. Cohn, LLP to remove its Development Stage Company classification. The company's revenues have been steadily increasing since their one-year R&D agreement with Pfizer Inc. (NYSE:PFE) in 2001 and 2002. As a result, the independent accountants have deleted the cautionary wording in its filings with the SEC.
"We are delighted that the company's proprietary human liver cell lines being delivered to major pharmaceutical companies are meeting their research requirements and expectations. As the drug discovery market develops and gains momentum, we can begin to focus on other applications for the company's cell lines," Jerry Newmin, chairman and chief executive officer stated.
Greg Szabo, president of Exten, added, "We are very pleased to progress to the commercialization phase by providing a vital product to the pharmaceutical industry. We believe that our human liver cells will become the 'gold standard' for testing of new compounds in the drug discovery process. Exten is currently in discussions with several additional pharmaceutical firms that are testing Exten's liver cell lines with positive results. We anticipate new purchase commitments within the next two quarters."
Exten provides pharmaceutical companies with liver cells for drug discovery through its subsidiary, MultiCell Technologies Inc. (MultiCell). The importance of using actual human liver cells for testing is the potential reduction in both cost and time to market: According to the Pharmaceutical Research and Manufacturers of America, an industry trade group, only one in 5,000 compounds tested in the laboratory becomes a new drug, and it takes an average of 12 to 15 years to bring a drug to market, at a cost of over $500 million.
MultiCell intends to develop its own cell based toxicological and drug screening tests. MultiCell is also investigating its highly specialized immortalized liver cell lines for various diagnostic and therapeutic uses, including the production of therapeutic proteins and liver stem cell transplantation. MultiCell's liver cells may also be utilized in applications such as Exten's Sybiol(R) synthetic bio-liver device.
Exten's Xenogenics Corp. subsidiary is still in the R&D phase with the Sybiol(R) synthetic bio-liver. The company believes its Sybiol(R) bio-liver device and other competitive liver assist devices will be optimized by the use of MultiCell's liver cells.
Exten is headquartered in Warwick, Rhode Island. Past news and more information are available on Exten's Web site, http://www.exten.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: MultiCell Technologies
Ron Faris, Ph.D., 401/738-7560
http://www.engelpub.com/news/show_article_f.asp?articleID=81734&catid=_main
exti was very active today and looked as if it is basing out...i think, i hope..i bought back in heavy just on my gut feeling..i have found it hard to get research information on this company so i am very grateful for those responsible for puttimg this board togather..thank you..good luck longs ..now i look forward to digging through the information provided here..keep it coming..
GlycoFi and Exti, differences, opinion of a poster
From: "canaani" xxxxxxxxxxxxxxx
Date: Thu Nov 13, 2003 8:32 am
'''I hope to shed some light on the difference (IMO) between the therapeutic proteins derived from EXTI cells and proteins generated by the yeast cells of GlycoFi.
Liver cells are complex "protein factories". They produce a plethora of enzymes and factors critical to normal metabolism. These proteins are highly complex and are very often species specific. That is a protein derived from a pig for example, may not be recognized or effective in the human body.
As I understand it, glycosylation the key to the GlycoFi technology. Glycosylation is one metabolic process by which a specific protein is "tagged" for its appropriate site of activity- sort of a key if you will. This would be a final step in creating a functional protein therapeutic from yeast cells. The first step, because yeast cells do not inherently produce these human proteins of interest, would require the insertion of the genetic blueprint for their manufacture. Assuming this geneticly engineered cell functions precisely as designed, studies of that "designer protein" to determine its integrity, safety, and efficacy as a therapeutic would be decidedly complex. The engineering process would be unique to each protein of interest and require validation of each yeast cell line and proein as it is established.
Alternatively, the EXTI human liver cells are potentially capable of generating native human proteins! These cell lines may be modified or optimized for specific protein production, but the "manufacture process" is inherently available. The minimal manipulation of the human liver cell lines should reduce the pathway to FDA approval relative to yeast derived proteins, which translates to reduced cost and timelier product to market.
This is my understanding of the technology- in any case. I hope it helps.
Snippet"""
GlycoFi and therapeutic proteins..possible competitor or customer? Can they mass produce therapeutic proteins?
http://www.glycofi.com/newsroomsuccess.php
This is a privately-held company.
Dartmouth Engineers Closer To Mass-producing Therapeutic Proteins
Hanover, N.H. (April 17, 2003) -- Dartmouth engineers are one step closer to mass-producing therapeutic proteins desperately needed by today's pharmaceutical industry.
Reported in today's early online edition of the Proceedings of the National Academy Of Sciences, the researchers have achieved a major milestone in their efforts to effectively produce human therapeutics using a yeast-based protein expression system.
The research is the result of a collaborative effort between Dartmouth researchers and a bioengineering startup called GlycoFi, Inc. Founded by two Dartmouth engineering professors, GlycoFi is advancing technological solutions for the safe, fast, and cost-effective mass-production of fully-humanized proteins. Protein-based biological drugs must be manufactured by living cells, which are genetically engineered to produce (or express) proteins that mimic the structures synthesized by humans. Current production of these therapeutic proteins is being pushed beyond capacity by exponential growth in the biopharmaceutical industry. GlycoFi's business is to engineer fungal expression systems that produce therapeutic proteins with human-like structures at an industrial scale.
"Production capacity has led to a bottleneck within the biopharmaceutical pipeline," said Charles Hutchinson, co-founder and CEO of GlycoFi, as well as dean emeritus of Dartmouth's Thayer School of Engineering. "The result is that some approved therapeutic protein drugs cannot be produced in adequate amounts, and still others are not making it into commercialization due to the cost and inefficiencies of producing them. It is our hope that this push to producing homogeneous, human-like glycoproteins in yeast will eliminate the production capacity bottleneck, and allow for the production of better and safer drugs."
Fungal-based protein expression systems are safer than conventional mammalian cell culture systems, but have not been effective in replicating complex human glycoprotein structures--until now.
"Demonstrating for the first time the production of 'hybrid' glycosylation structures in yeast brings GlycoFi an important step closer to dramatically improving the capacity and cost of producing therapeutic proteins," said Tillman Gerngross, Dartmouth engineering professor, co-founder and chief scientific officer of GlycoFi, and one of the authors on the paper. "In fact, we have already gone beyond this work and expect to manufacture fully complex human glycoproteins in one of our fungal production systems before the year's end."
Dartmouth/GlycoFi scientists genetically engineered the yeast P. pastoris to perform a series of sequential reactions that mimic the early processing of proteins in humans. After eliminating non-human glycosylation from the yeast, several genes were inserted into the yeast in such a way that the yeast synthesized new human-like glycosylation structures.
"The glycosylation structures we are seeing in our yeast are of a purity and uniformity unprecedented in biopharmaceutical manufacturing," said Stefan Wildt, also a Dartmouth engineering professor, director of strain development at GlycoFi, and another author of the paper. "This will allow GlycoFi to harness the inherent advantages of fungal protein expression systems and thereby address the biopharmaceutical manufacturing industry's capacity issues."
From Netguy post
SEC filing re PFIZER, revenue and Alandail summary from RB #13851
From the 10-K
On November 1, 2001, MultiCell entered into a collaborative research agreement with Pfizer, Inc. pursuant to which Pfizer paid $724,500 to validate the efficacy of MultiCell's immortalized hepatic cells in four different experimental models. These cells, if effective, could replace the current hepatocytes used by Pfizer as well as other pharmaceutical companies. The efficacy of these cell lines was demonstrated and presented by Pfizer at the International Society for the Study of Xenobiotics ("ISSX") in October 2002.
This led to the validation they needed that first led to this being in the May 31 Q
The Company has had discussions with more than a dozen companies interested in acquiring our engineered cells for research. We have received orders from three major pharmaceutical companies where efficacy evaluation is currently taking place. We believe that some of these discussions and evaluations can be brought to a conclusion in the near future. The agreements may produce cash to use for operations and research.
And also led to the deal with XenoTech - XenoTech saw Pfizer's presentation and first did their own validation and then went after EXTI to make that $18 million guaranteed minimum deal. We also know Roche has now validated and extended Pfizers results.
Sure, there is a process involved in getting companies to switch over to EXTI's cell lines. But don't think that process just started a few weeks ago - the process has been going on for at least 6 months now. Roche did this research and concluded in their presentation:
In summary, Fa2N-4 cells are a convenient and viable alternative to primary human hepatocytes for evaluating the potential of investigational compounds to induce Drug Metabolizing Enzymes and Drug Transporters.
Wouldn't it be a fair conclusion that anyone who did this research and reached these conclusions would already be a customer for XenoTech?
- - - - -
NEWS 10/30/2003 MultiCell CEll Lines Introduced Worldwide
http://finance.lycos.com/qc/news/story.aspx?symbols=BB:EXTI&story=200310301908_BWR__BW5610
MultiCell Cell Lines Introduced Worldwide as New Findings Expand Potential Use of MCT Technology
30 October 2003, 2:08pm ET
WARWICK, RI--(BUSINESS WIRE)--Oct. 30, 2003--Exten Industries Inc.'s (Exten) (OTCBB:EXTI) wholly owned subsidiary, MultiCell Technologies Inc., (MCT) announced today that its exclusive distribution partner, XenoTech LLC, has introduced MCT's technology at three prominent drug discovery meetings, as new results reported by scientists from XenoTech and Roche independently validate the reproducibility of MCT's cell lines as a valuable tool in pharma's R&D arsenal to characterize new drug candidates.
This week, XenoTech marketed MCT products at the American Association of Pharmaceutical Scientists (AAPS) 2003 meeting in Salt Lake City. According to the AAPS, their annual meeting and exposition is "the largest gathering of pharmaceutical scientists in the world."
Earlier this month XenoTech scientists presented new and promising results showing how MultiCell's liver cell lines can be used to better characterize new drug candidates prior to entry into clinical studies. The presentations were heard by audiences of over 400 pharmaceutical scientists gathered from all over the world who attended the 12th annual meeting of the International Society for the Study of Xenobiotics (ISSX), held October 12 - 16 in Providence, RI and the 18th annual meeting of the Japan Society for the International Study of Xenobiotics (JSSX) held October 8 - 10 in Sapporo, Japan.
XenoTech Founder and CEO, Dr. Andrew Parkinson, states, "Our characterization studies corroborate and extend the earlier findings of MultiCell and Pfizer scientists presented at the 2002 ISSX meeting. Our results show that MCT's immortalized hepatocytes retain several functional drug metabolizing enzymes that previously had not been studied." Dr. Parkinson adds, "MCT's cell lines represent a breakthrough technology that has the potential to revolutionize how the pharmaceutical industry screens new drug entities, we anticipate significant worldwide interest in MCT's cell lines."
A presentation by scientists from Roche at the Providence ISSX meeting also concluded that MCT's "immortalized cells have potential for use as an alternative to primary human liver tissue for in vitro induction studies."
Mentioned Last Change
EXTI 1.02 0.18dollars or (21.42%)
Ronald A. Faris, Ph.D., MultiCell president and chief scientific officer, offers, "The XenoTech and Roche results are very significant. Not only have these laboratories confirmed that MCT cell lines are a reliable tool to study induction of key drug metabolizing proteins, but more importantly, taken together these findings indicate that our immortalized hepatocytes can be employed to study the complex metabolism of new drug candidates and identify potential drug-drug interactions. We anticipate that the greatest impact of MCT technology will be to red-flag those new drug candidates that may have undesirable side effects much earlier in the overall drug discovery process, thus providing significant savings to the pharmaceutical industry."
Dr. Faris added that "MultiCell's global sales, marketing and production agreement with XenoTech will allow us to re-direct our own efforts upon developing therapeutic applications for our highly functional liver cells, thereby, hopefully, opening up new markets for our other potential products."
Copies of the XenoTech and Roche scientific presentations can be requested at info@multicelltechnologies.com .
About Exten:
Exten Industries Inc., through its two subsidiaries Xenogenics Corporation and MultiCell Technologies Inc., is engaged in developing liver-based products in the medical device, therapeutic and pharmaceutical testing arenas. Xenogenics is developing the Sybiol(R) synthetic bio-liver device. MultiCell provides hepatic (liver) cells and cell lines to pharmaceutical companies, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Exten's corporate and research headquarters are in Warwick, RI. For more information about Exten and its subsidiaries, visit www.exten.com .
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Exten Industries Inc., Warwick
Ron Faris, 401-738-7560
SOURCE: Exten Industries
NEWS 11/7/2003..Notice of Liver Device Patent
http://finance.lycos.com/qc/news/story.aspx?symbols=BB:EXTI&story=200311071330_BWR__BW5096
Exten's Xenogenics Subsidiary Gets Notice of Liver Device Patent
7 November 2003, 08:30am ET
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 7, 2003--Exten Industries Inc. (Exten) (OTCBB:EXTI) announced today that its majority owned subsidiary, Xenogenics Corp. ("Xenogenics"), has received a notice of allowance from the U.S. Patent and Trade Office that its Sybiol(R) synthetic bio-liver device patent will be issued in the next few months.
Jerry Newmin, chairman and CEO of Exten, commented, "We have worked and waited a long time for this patent. It has the possibility of helping hundreds of thousands of people with liver trauma or insufficiency around the world. This original patent was based on the use of primary pig hepatocytes (liver cells). As there have been many design advances since the initial patent filing, including a switch to MultiCell's immortalized liver cells, we intend to file additional new patents covering recent improvements to this device. The team at MultiCell has been instrumental in building a promising new prototype that is ready for initial animal testing."
Mentioned Last Change
EXTI 1.02 0.18dollars or (21.42%)
Xenogenic's synthetic bio-liver device has been re-designed to utilize the immortalized human liver cells lines developed by Exten's wholly owned subsidiary Multicell Technologies Inc. ("MultiCell"). Greg Szabo, president, added, "Our two subsidiaries have worked together to redesign and enhance the Sybiol(R) device around MultiCell's highly functional liver cell lines. Liver diseases affect about one out of every 10 Americans and that incidence appears to be increasing," he added. "Our Sybiol(R) device may well prove someday to be a useful tool in treating these patients."
The Sybiol synthetic bio-liver is an extra-corporeal device designed to support patients who are waiting for liver transplants, who are suffering from episodic liver disease caused by hepatitis, alcoholism, cancer, or from burn or toxic shock syndrome or other liver trauma. The device is designed to increase not only the life spans, but also the quality of life in afflicted patients.
About Exten:
Exten Industries Inc., through its two subsidiaries Xenogenics Corp. and MultiCell Technologies Inc., is engaged in developing liver-based products in the medical device, therapeutic and pharmaceutical testing arenas. Xenogenics is developing the Sybiol(R) synthetic bio-liver device. MultiCell provides hepatic (liver) cells and cell lines to pharmaceutical companies, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Exten's corporate and research headquarters are in Warwick, RI. For more information about Exten and its subsidiaries, visit www.exten.com .
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Exten Industries Inc., Warwick
Greg Szabo or Jerry Newmin, 401-738-7560
SOURCE: Exten Industries Inc.
Gerald Newmin/interview/August 2001
EXTI Chairman and
Chief Executive Officer
Here is an old interview of Gerald Newmins dated August 2001 with a bit of bio on him
http://www.ceocfointerviews.com/interviews/ExtenInd.htm
Healthcare
Biotech
Medical Equipment
OTC BB: EXTI
Exten Industries, Inc.
9620 Chesapeake Dr., Suite 201
San Diego, CA 92123
Phone: 858-496-0173
Gerald Newmin
Chairman and
Chief Executive Officer
Interview conducted by:
Walter Banks, Co-Publisher
CEOCFOinterviews.com
August 2001
BIO OF CEO
Jerry Newmin has managed NYSE and American Exchange-listed Fortune 500 companies and start-ups, specializing in turning around troubled companies and improving revenues, profits and shareholder value. He has been President of HealthAmerica and International Silver Company, CEO of numerous Whittaker Divisions, VP of American Medicorp, CEO of SYS and Chairman of International Forum for Corporate Directors. Additionally, Jerry is Chairman, Treasurer and Director for Xenogenics Corp.
About
Exten Industries, Inc.
Exten Industries, Inc., through its Xenogenics Corporation subsidiary, is engaged in the business of managing the research and development and commercialization of the Sybiol® synthetic bio-liver, an "artificial liver" or liver support system. The Sybiol® liver device is based on technology for continuously circulating liver cells (hepatocytes) through a semi-permeable bio-membrane.
On April 2, 2001, Exten Industries, Inc. announced that they had signed a Letter of Intent to acquire its research and development partner, privately held MultiCell Associates, Inc. (MultiCell) of Warwick, RI in a cash plus stock transaction. Specific details were not disclosed. This acquisition will solidify the working relationship between the two firms in their joint liver assist device program.
MultiCell is a highly respected research company with unique expertise in developing functional cells and cell lines with a special focus on liver derived cells. They have several patents issued on their immortalized hepatocytes or engineered liver cells. MultiCell’s mission, to develop and commercialize cells for diagnosis and treatment of liver diseases, has resulted in an exclusive non-tumorigenic DNA-engineered porcine hepatocyte cell line. Exten has redesigned their device to operate with the MultiCell technology using DNA engineered liver cells.
The Sybiol® liver therapy device is intended to be used as an artificial liver "bridge" for transplant patients when no donor organ is available, and, via regular outpatient treatments, maintain essential liver functions for patients with chronic liver disease or other liver trauma until the human liver heals and is able to resume normal liver functions. It may also increase the quality of life in those patients who are not curable. Lastly, the device may be an effective tool for laboratory testing, veterinary applications, and/or drug testing applications.
CEOCFOinterviews - Mr. Newmin, can you give us a brief history of Exten Industries?
Mr. Newmin: "Exten has been around for a long time, but my involvement began in late 1995. The company acquired the artificial liver device technology from a major medical center in Los Angeles in l993. Exten then stopped all its other activities and concentrated solely on an external biological device to artificially perform some of the basic functions of the human liver. The device is trademarked Sybiol® for synthetic bio-liver.
CEOCFOinterviews - Where is your external liver device in its development?
Mr. Newmin: "The original design of the device was used with liver cells that were extracted from live pigs. We were conducting our research at Loyola Medical Center in Chicago. However, it became apparent that, with both the FDA and the public, dealing with animal retro viruses was going to be a problem. We found a company called MultiCell Associates in Warwick, Rhode Island that developed and patented DNA engineered cells that were manufactured in a laboratory. Therefore, we switched all of our research and development over to MultiCell last year, using DNA engineered pig liver cells. That required redesigning our device. This new device has now restarted testing, and our goal is to use it on large animals, primarily pigs. Following these tests and developing enough hard data, we will file an IND application with the FDA preparatory to initiating Phase 1 safety testing."
CEOCFOinterviews - Do you have any projections as to when clinical trials may start?
Mr. Newmin: "We plan to complete animal trials later this year, and then we plan to start clinical trials in 2002. It is not entirely clear as to exactly how long it will take to get to Phase II and Phase III of the FDA trials. We feel it may take 3 to 5 years. That depends on how many patients the FDA will require to be tested."
CEOCFOinterviews – What will your relationship with MultiCell Associates be going forward?
Mr. Newmin: "MultiCell will be a wholly owned subsidiary of Exten. The owner of MultiCell Associates, an internationally known scientist, unfortunately passed away and his estate decided to sell the company. We have signed a Letter of Intent to acquire the company and are in final stages of closing that transaction. Acquiring MultiCell will allow us to keep all of our research in house. Moreover, the acquisition also gives us the exclusive right to the cell lines. Multicell has developed a human liver cell that they can manufacture in laboratories. Therefore, our hope is to test the device with the human liver cell, which clearly will be a more approvable process than the use of pig liver cells. Since the human liver cell has some significant opportunities for toxicity testing, we think that other products may evolve from these cell lines. Sometime in the future we may consider the merger of MultiCell with our subsidiary Xenogenics Corporation, which owns the artificial liver technology."
CEOCFOinterviews – What changes have you made in the Sybiol® device technology since its acquisition?
Mr. Newmin: "There were certain problems with the technology. Therefore Dr. Brems, the chairman of our advisory board and a member of the staff of the transplant program at the Loyola University came up with some innovative ideas, unique in terms of the way these cells were presented to the patient plasma. That resulted in a patent that is now working it’s way through the patent office. Our objective is to develop a device where the cells stay alive for long periods, therefore extending their viability in terms of their interface with the patient blood. That makes the treatment more efficacious and at the same time drives down the cost per treatment. As an example, the Sybiol® is a device designed to be a "bridge" for transplant patients, when no donor organ is available and, via regular outpatient treatments, maintain essential liver functions for patients with chronic liver disease and other liver trauma until the human liver heals. Our goal is to be able to slow down the rate at which the liver is going to fail or, if we are fortunate, prevent the liver from failing altogether.
The liver is the only organ that will rejuvenate itself, if you allow it. A family member or close relative can literally donate a part of their liver to another family member with a liver failure and the donor's liver will grow back quite quickly. The idea here is to provide “off-line” help to the liver so that it can rejuvenate itself throughout these diseases and allow the patient to lead a normal life.”
CEOCFOinterviews - Can you give us a little more detail on how that would work?
Mr. Newmin: "With kidney dialysis you go for periodic treatments into an outpatient center, where they purify your blood. With our Sybiol device, the patient would go to a similar kind of facility. We do not know exactly how often or how frequently or how long the treatments would be; that would depend on their individual condition. However, you would essentially run a patient’s blood through our device exposing its plasma to the cells contained within our device. There would then be an interaction between the cells in our device and the patient blood plasma where the cells actually perform some of the functions of the liver, including de-toxification. It will probably happen at an outpatient dialysis center, because everything you need for this type of dialysis is already there. We probably would have liver dialysis departments, just as there are kidney dialysis departments."
CEOCFOinterviews – How will you approach the market place?
Mr. Newmin: "We believe the market is very large. The market is not just transplants - there are only about four thousand transplants a year done in the United States. However, because Hepatitis, particularly Hepatitis C, is on the rise all over the world, the business opportunity for a liver assist device is probably as large as or larger than kidney dialysis, which is in the hundreds of millions. We will talk to some of the key players in the major pharmaceutical companies as soon as we have good hard data and are in FDA trials. We will attempt to partner with someone who has much better resources to put our device out to the market than we do."
CEOCFOinterviews – Can you give us an idea of the current cost in treating liver disease?
Mr. Newmin: "It is a very expensive process. For example, it costs over $300,000 for a liver transplant. Our goal is to get the outpatient treatment with dialysis down to close to what kidney dialysis runs. That could be in the thousands of dollars per treatment, yet it is certainly is not in the hundreds of thousands, which is what a transplant would cost. There are a number of treatments that can help the diseased liver, yet they are all very expensive."
CEOCFOinterviews - What other revenue generating possibilities are there for the MultiCell Company?
Mr. Newmin: "MultiCell has a potential to be in the business of selling cells to the pharmaceutical industry. We have already held discussions with several companies and they were very excited about this product. That business opportunity is probably as great as the liver technology’s potential. We think we will be selling some of these cells within months after we close the acquisition. That should happen this year and will be generating revenues and hopefully profits. This is a very exciting business opportunity for us, selling to pharmaceutical firms and research companies.
MultiCell is the only company that has engineered human liver cells. Other people are growing cells using tumorigenic cells, because they proliferate rapidly. MultiCell developed a line of cells that can be replicated and produced in a laboratory that are non-tumorigenic, DNA engineered in origin."
CEOCFOinterviews – Will you be looking to make any more acquisitions?
Mr. Newmin: "We were looking at acquiring some other companies, for example we would like to acquire a medical device manufacturing company, because we would want to be able to manufacture the device, the Sybiol synthetic bio liver, and the disposable products ourselves. In all, we intend to be selling three products. The device itself, the disposable kit issued to each patient at the time of treatment and the cells that would then be applied to the patient as needed. Therefore, we would like at some point to vertically integrate all those activities."
CEOCFOinterviews - Are there any other companies working on a device for liver dialysis?
Mr. Newmin: "There are companies experimenting with liver dialysis, however, none of them is doing it in the fashion we are. We are truly unique in that we suspend our cells in a solution as opposed to growing or packing them in the device itself. There is also another company, which kills pigs to extract liver cells, freezes them and then puts them into the device. We try to create a friendly environment for the cells. The fact that we manufacture the cells eliminates major concerns of the FDA."
CEOCFOinterviews - Do you have the cash or credit to continue going forward?
Mr. Newmin: "We are always raising money. We raised over a million dollars in the last 12 months from a group in Dallas, and now we are in the process of raising more, both to close the acquisition of MultiCell and to cover operating expenses. Beyond that we will be trying to form an alliance with a major financial partner, a strategic partnership for the major money required for the FDA trials."
CEOCFOinterviews – In closing, what would you like to say to your current shareholders and potential investors?
Mr. Newmin: "I think we are at a very exciting point where the company is clearly about to make a major breakthrough in terms of the new cell line and the way the cells work in our device. We also have a patent for our technology that, we hope, will be issued shortly. We have additional patentable processes that are evolving in our new design concept. We believe that we are in a good position looking forward.
This company has been around for a long time. Since I have been involved, I have never questioned or doubted any of our doctors or scientists, and have always believed that we could develop a device that would work. I think that the addition of MultiCell is the most exciting thing that could happen to us. Where we are today was once only a dream, and we have done it quite rapidly. I think that the MultiCell acquisition is an incredible opportunity, and if we can do even a part of what we think we can, our shareholders will be very happy."
Pfizer calls on MultiCell to predict toxicological and therapeutic properties of drug candidates
FRIDAY , NOVEMBER 16, 2001 07:24 AM
Nov 16, 2001 (Datamonitor via COMTEX) -- Exten Industries(OTCBB: EXTI .13) wholly owned subsidiary, MultiCell Technologies, has signed a Collaborative Research Agreement with Pfizer. The agreement with involves validation of MultiCell's immortalized liver cells to predict, among other things, the toxicological and therapeutic properties of drug candidates.
"We believe that our cells may profoundly impact the drug discovery paradigm," stated Greg Szabo, acting CEO of MultiCell, in a media release. "We envision that the cell lines provided by MultiCell will facilitate early identification of potentially harmful side effects such as drug-drug interactions. As a result, our technology may ultimately lead to more efficient and cost effective production of new drugs. We believe that Pfizer is the first of many pharmaceutical companies that can benefit from our technology."
Neither party disclosed specific terms of the agreement.
URL: http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
Copyright (C) 2001 Datamonitor. All rights reserved
Disclaimer
http://www.investorshub.com/boards/read_msg.asp?message_id=135097
Greg Szabo recent stock sale, he explains in email
There might be some questions in your mind when you find out that Mr. Szabo sold some of his stock in EXTI.
Hopefully, the following post copied and pasted from RB, EXTI thread will help you.
By: exticat
01 Nov 2003, 02:46 PM EST
Msg. 9658 of 12315
Jump to msg. #
LISTEN UP EXTIheads: Email from Greg Szabo
This is part of an unsolicited email I received yesterday from Greg Szabo. It is self-explanatory and should put some minds at ease. Personally, I've never had reason to doubt the integrity of our stellar management team. EXTIcat^$^
---------------------------------------------------------
From: "Greg Szabo"
To: "'XXXXXX XXXXXXXXXX
Date: Fri, 31 Oct 2003 08:29:59 -0800
Please do me a favor. I know you are a watcher of raging bull. I was told that there has been comments on my stock sale. If this is true, I would appreciate a comment from you explaining that I take part of my salary in stock to preserve cash for the company. Because of this, when it is appropriate, I need to sell some stock to pay for some personal needs like two kids in college. I can’t trade Exten stock for tuition. In no way is an indication that I don’t believe in what we are doing or where we are going. FYI, Jerry takes all of his compensation in stock. Thanks, greg
MultiCell Technologies has developed an exclusive proprietary process for indefinitely growing healthy "immortalized" human liver cells which can be grown quickly in large batches for use by the pharmaceutical industry and research institutions worldwide to expedite drug discovery development and drastically reduce R&D costs. These immortalized human liver cells function much as they would in living persons and are used by researchers to test toxicity of experimental compounds before expensive and potentially dangerous testing on humans. The market for these humanized cells is estimated to be in the billions of dollars which has really caught our attention. In addition, these replicable healthy human cells can produce various proteins, etc., which have the potential to be used and engineered for other therapeutic uses which MultiCell is also investigating.
MultiCell recently signed a 15-year agreement to supply these cells to Pfizer Pharmaceuticals and has also just signed another agreement with a premier privately held cellular biotech manufacturing and marketing firm to begin producing and marketing its immortalized human liver cells to other pharmaceutical firms in the U.S., Europe and Japan.
From http://www.exti.info
EXTI....THIS IS A PRIMER TO SYBIOL>>>UNDERSTANDING HOW IT WORKS
Principles of Liver Support Systems
Erika Olson, Erin Bradley and Kedar Mate
Our thanks to Dr. Hugo Jauregui of MultiCell Co. for his assistance and guidance in our attempt to understand the bioengineering, cell biology, politics and economics of the bioartificial liver.
http://biomed.brown.edu/Courses/BI108/BI108_1999_Groups/Live...
Xenotech and Xenogenics as they fit with Exten
RB post on EXTI thread # 8775
Xenotech and Xenogenics are not related.
Xenogenics is an Exten subsiduary that is working on the Sybiol.
XenoTech is MultiCell's new distribution partner
"How Liver Maintains Body's Health"
-------------------------------------------
The liver is the human body's largest organ and weighs between three and five pounds in adults. It lies in the abdominal cavity on the right side under the rib cage and in contact with the diaphragm. In appearance, the liver is a glossy dark red due to the rich supply of blood flowing through it. In humans the liver is divided into two lobes, the right lobe measuring six to seven inches in length and the left closer to three inches in length. The gallbladder is located on the under surface of the liver's right lobe.
The liver is responsible for many vital life functions, which can be divided into three basic categories:
Regulation, synthesis, and secretion of substances key to maintaining the body's health
Storage of important nutrients including glycogen (glucose), vitamins A, D, B-12, and iron for release as needed by the body
Detoxification of the body: The liver must break down every substance toxic to the body including metabolic wastes (e.g. ammonia), insecticide and pesticide residues, drugs, alcohol, etc. Failure of this function will usually cause death in 12 to 24 hours.
An understanding of the liver's structure is key to understanding its function-and possible dysfunction. Of primary importance is the liver's vascular system. Only 25% of the liver's blood supply is arterial blood (coming from the heart). The remaining 75% of the liver's blood supply is venous blood (returning to the heart) from the portal vein. All of the venous blood returning from the small intestine, stomach, pancreas, and spleen converges in the portal vein, which means that everything absorbed by these organs hits the liver first. The liver then processes, stores, or eliminates these substances as needed by the body.
The nature of the liver's work necessarily exposes it to a number of threats, and it is also one of the organs most susceptible to injury. The working cells of the liver, called hepatocytes, are unique in their capacity to regenerate in response to liver injury or even after the surgical removal of part of the liver. This remarkable ability to react to damage and repair itself can, however, be compromised by repeated abuse, which can lead to liver failure and death.
The signs and symptoms of an unhealthy liver can include:
A tendency to bleed
Mental changes, such as confusion
Decreased growth (in children)
Jaundice
Ascites (fluid in the abdomen)
Dark urine
Clay-colored stools
A blood test known as a "liver panel" will show an increase in liver enzymes in the bloodstream. These enzymes are released by dead liver cells and indicate that damage to the liver has occurred due to any number of factors.
How the Liver Maintains the Body's Health
Produces and excretes bile, which is stored in the gallbladder and aids in the digestion of foods. Bile salts (a component of bile) emulsify fats and the fat-soluble vitamins A, D, E, and K for proper absorption. The liver also removes some fat-soluble toxins from the body.
Metabolizes proteins, including those responsible for normal blood clotting. The liver converts various amino acids into others as needed.
Converts the thyroid hormone thyroxine (T4) into it more active form triiodothyronine (T3). The results of incomplete conversion can include hypothyroidism, chronic fatigue, weight gain, poor memory, and other debilitating conditions.
Creates GTF (Glucose Tolerance Factor) from chromium, niacin, and possibly glutathione. GTF is a necessary component in the proper regulation of blood-sugar levels.
Activates B vitamins into their biologically active coenzyme forms. The liver must transform nearly all nutrients into the biochemical forms that allow the body to store, transport, or use those nutrients.
Manufactures carnitine from lysine and other nutrients. Carnitine is a bionutrient that escorts fats into the mitochondria where they are used to generate ATP energy.
Extracts lactic acid from the bloodstream and converts it from a toxic waste to glycogen, an important reserve endurance fuel. Lactic acid is a byproduct of the metabolization of glucose and causes muscles to become sore when it accumulates.
Produces cholesterol and converts it into the various forms needed for blood transport.
Converts essential fatty acids such as GLA, EPA, and DHA into the lipoprotein forms necessary to allow transport via the bloodstream to the 50 trillion cells requiring fatty acids.
-------------------END----------------------------------
By: ttggggtt0
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12280
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
141
|
Created
|
11/08/03
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |